|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2011-4-26
|
|
pubmed:abstractText |
Inhibiting A? generation is a prime therapeutic goal for preventing or treating Alzheimer disease. Here we sought to identify any disease-modifying properties of an azaindolizinone derivative, spiro[imidazo[1,2-a]pyridine-3,2-idan]-2(3H)-one (ST101 or ZSET1446).
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Amyloid beta-Protein Precursor,
http://linkedlifedata.com/resource/pubmed/chemical/Amyloidogenic Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Cathepsin D,
http://linkedlifedata.com/resource/pubmed/chemical/Indans,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/Spiro Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Tubulin,
http://linkedlifedata.com/resource/pubmed/chemical/amyloid beta-protein precursor...,
http://linkedlifedata.com/resource/pubmed/chemical/spiro(imidazo-(1,2-a)pyridine-3,2-in...,
http://linkedlifedata.com/resource/pubmed/chemical/tau Proteins
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1531-8249
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2010 American Neurological Association.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
69
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
831-44
|
|
pubmed:meshHeading |
pubmed-meshheading:21416488-Age Factors,
pubmed-meshheading:21416488-Amyloid beta-Protein Precursor,
pubmed-meshheading:21416488-Amyloidogenic Proteins,
pubmed-meshheading:21416488-Animals,
pubmed-meshheading:21416488-Brain,
pubmed-meshheading:21416488-Cathepsin D,
pubmed-meshheading:21416488-Cell Line, Tumor,
pubmed-meshheading:21416488-Disease Models, Animal,
pubmed-meshheading:21416488-Dose-Response Relationship, Drug,
pubmed-meshheading:21416488-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:21416488-Humans,
pubmed-meshheading:21416488-Indans,
pubmed-meshheading:21416488-Macaca fascicularis,
pubmed-meshheading:21416488-Maze Learning,
pubmed-meshheading:21416488-Memory,
pubmed-meshheading:21416488-Mice,
pubmed-meshheading:21416488-Mice, Transgenic,
pubmed-meshheading:21416488-Molecular Weight,
pubmed-meshheading:21416488-Neuroblastoma,
pubmed-meshheading:21416488-Peptide Fragments,
pubmed-meshheading:21416488-Proteomics,
pubmed-meshheading:21416488-Reaction Time,
pubmed-meshheading:21416488-Schizophrenia,
pubmed-meshheading:21416488-Spiro Compounds,
pubmed-meshheading:21416488-Subcellular Fractions,
pubmed-meshheading:21416488-Transfection,
pubmed-meshheading:21416488-Tubulin,
pubmed-meshheading:21416488-tau Proteins
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
ST101 induces a novel 17 kDa APP cleavage that precludes A? generation in vivo.
|
|
pubmed:affiliation |
From the Department of Neurobiology and Behavior Institute for Memory Impairments and Neurological Disorders, University of California at Irvine, Irvine, CA 92697-4545, USA. kngreen@uci.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
